We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. FDA Issues Guidance on Special Controls for Cystic Fibrosis Assays
U.S. FDA Issues Guidance on Special Controls for Cystic Fibrosis Assays
February 6, 2007
Medical device firms should establish special controls to ensure the safety and effectiveness of quality control (QC) materials for cystic fibrosis nucleic acid assays, according to U.S. Food and Drug Administration (FDA) guidance published Jan 10.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor